华蟾素经肝动脉栓塞灌注给药治疗中晚期原发性肝癌的系统评价  

Transcatheter arterial chemoembolization with cinobufacini infusion for advanced primary liver cancer:a systematic review

作　　者：田怀平[1] 杨宇[1] 杨萍[1] 唐跃年[1] 

机构地区：[1]上海交通大学医学院附属新华医院药学部,200092

出　　处：《环球中医药》2016年第10期1175-1179,共5页Global Traditional Chinese Medicine

摘　　要：目的用Meta分析的方法系统评价华蟾素经肝动脉化疗栓塞术灌注给药治疗中晚期原发性肝癌的疗效及安全性。方法计算机检索Pub Med、The Cochrane Library、EMbase、VIP、Wan Fang Data、CBM和CNKI数据库,检索时限为从建库至2015年12月,收集华蟾素经肝动脉栓塞术治疗中晚期原发性肝癌的临床试验。由两位研究者按照纳入与排除标准,独立进行文献筛选、资料提取和纳入研究的方法学质量评价,采用Rev Man 5.2软件进行Meta分析,并对发表偏倚进行检验。结果最终纳入7项研究,共计360例肝癌患者。Meta分析结果显示:华蟾素经肝动脉栓塞术灌注治疗中晚期原发性肝癌,疗效和化疗药物肝动脉化疗栓塞治疗相当,但能够明显改善生活质量,减少部分不良反应。结论华蟾素经肝动脉化疗栓塞灌注给药治疗原发性肝癌是一种较好的治疗方案。Objective To assess the efficacy and safety of transcatheter arterial chemoembolization with cinobufacini infusion for advanced primary liver cancer. Methods Databases such as PubMed, The Cochrane Library, EMbase, VIP, WanFang Data, CBM and CNKI were searched for clinical trials on transcatheter arterial chemoembolization（TACE） with cinobufacini infusion for advanced primary liver cancer from create database to December 2015. Two researcher independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality. Meta-analysis was performed by RevMan 5.2. Results Seven trials were included and involved a total of 360 patients. The results of meta-analysis showed that： The cinobufacini infusion group was equal to the chemotherapy drug TACE group in terms of short-term efficacy and long-term efficacy, improved the quality of life, caused less adverse reaction partly. Conclusion TACE with cinobufacini infusion is better choice for advanced primary liver cancer.

关 键 词：原发性肝癌 华蟾素 肝动脉化疗栓塞 Meta分析 系统评价 

分 类 号：R735.7[医药卫生—肿瘤]